Growth-Hormone Secretagogue Peptides

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

A modified GHRH (1-29) analog without the Drug Affinity Complex — produces discrete, pulsatile GH release with a ~30-minute half-life, closely mimicking endogenous GH secretion patterns.

An early-generation growth-hormone-releasing peptide with potent GHSR agonism but notable prolactin elevation compared to the later selective agent Ipamorelin.

The first-generation growth-hormone-releasing peptide, notable for inducing strong hunger through ghrelin-receptor activation alongside GH release.

A potent GHRP with documented cardioprotective effects in ischemic animal models, distinct from other GHRPs in its non-GH receptor activity.

A modified fragment of human growth hormone (amino acids 176-191) that retains GH's lipolytic activity without its growth-promoting or diabetogenic effects. The most targeted fat-loss peptide in research use.

An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.